Pfizer's 2026 revenue midpoint of $61B and EPS midpoint of $2.90 decline YoY, reflecting persisting headwinds. Read more on ...
Zacks Investment Research on MSN
Pfizer Inc. (PFE) is attracting investor attention: Here is what you should know
Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...
Pfizer (PFE) stock has attracted fresh attention after recent trading left its one-month return at a 3.3% decline and its ...
Barchart on MSN
Pfizer's quarterly earnings preview: What you need to know
Pfizer Inc. (PFE), headquartered in New York, discovers, develops, manufactures, markets, distributes, and sells ...
Pfizer Inc. (NYSE:PFE) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 16, Pfizer Inc. (NYSE ...
Pfizer stock (NYSE: PFE) is currently in a significant slump, marking its ninth consecutive day of decline and losing a total of −11% of its value over that period. This sustained sell-off has wiped ...
SureCare Pharmacy manager Oscar Uribe shows off a package of Pfizer Paxlovid pills inside of Esperanza Health Center in Chicago on Jan. 13, 2022. Pfizer's Paxlovid is a treatment for COVID-19. (Chris ...
Pfizer enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution. Click here to read ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback